A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
A phase 2/3 trial testing HS-20117 in non-small-cell lung cancer, now recruiting.
Overview
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT06417008, led by Hansoh BioMedical R&D, and recruiting when checked on 2026-09-11. Official title: A Phase Ib/III Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Immunogenicity of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer. Planned enrolment is 1080 participants (estimated). The study started in 2024-05-28 and primary completion is expected in 2026-06-01. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Shares Hansoh Pharmaceutical, Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialStudy of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
Shares Hansoh Pharmaceutical and the tag ctgov-ingest.
- TrialHS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Shares Hansoh Pharmaceutical and the tag ctgov-ingest.
- TrialSSGJ-707 in Advanced Non-Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialSymbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Shares Non-small-cell lung cancer and the tag ctgov-ingest.